Tony Stripling Email & Phone Number

Bethesda, Md, Us

Vancouver, British Columbia, Ca

Advise pre-seed stage AI platform technology startup in the market research space, specifically focused on initial customer acquisition strategy, fundraising via investor network, and ad hoc corporate & product strategy development

Cambridge, Massachusetts, Us

Advised multiple oncology startups as part of mentor team through MassBio's Drive program:- Tezcat Biosciences: Protein Drug Conjugate platform- RedPoint Oncology: Drug Conjugate platform (e.g., ADC, oligonucleotide drug conjugates)

Cambridge, Cambridgeshire, Gb

Lead market research, forecasting, and advanced analytics for U.S., EU5, China, & Japan in early hepatocellular carcinoma (HCC), resectable/early and advanced biliary tract cancers (BTCs), locally advanced / unresectable esophageal squamous cell carcinoma (ESCC), and resectable gastric and gastroesophageal junction cancer (GC/GEJC)Responsible for insights and market assessment for cross-functional deliverables across multiple assets (e.g., I-O, ADCs, bi-specifics), including Tumor Strategy Plans for BTC, HCC, & Gastric CancersResponsible for insights and market assessment for brand deliverables in aBTCs, eHCC, GEJC/GC, and locally advanced ESCC

Cambridge, Cambridgeshire, Gb

Led forecasting for Immuno-Oncology (I-O) products in Neoadjuvant & Adjuvant Stage II-IIIb Non-Small Cell Lung Cancer (NSCLC), Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), Stage IV Metastatic Non-Small Cell Lung Cancer (mNSCLC), and Extensive Stage Small Cell Lung Cancer (ES-SCLC) for U.S. marketPartnered with Brand Strategy / Marketing teams to develop and execute commercial strategy across all forecasted indications (e.g., NSCLC, SCLC), including market segmentation, key performance indicator selection and targeting, AdBoards, market research (e.g., demand studies, patient journeys, drivers & barriers, etc.), and conference coverage (e.g., ASCO, AACR, ESMO)Conducted primary market research and forecasting buildout ahead of I-O product launch in Stage IV Metastatic Non-Small Cell Lung Cancer (NSCLC) and Neoadjuvant & Adjuvant Stage II-IIIb Non-Small Cell Lung Cancer (NSCLC) for U.S. marketConducted competitive intelligence across all I-O in-line and late-stage clinical pipeline indications (10+ indications) as well as build out comprehensive competitive intelligence database and presentation material for C-Suite Executives

Cambridge, Cambridgeshire, Gb

Led forecasting for Immuno-Oncology product in Extensive Stage Small Cell Lung Cancer (ES-SCLC) and Stage IV Metastatic Non-Small Cell Lung Cancer (mNSCLC) for U.S. marketManaged performance analytics for Immuno-Oncology product ($1B+ revenue) across all in-line lung cancer indications, including Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), & Stage IV Metastatic Non-Small Cell Lung Cancer (NSCLC) for U.S. market

Boston, Ma, Us

Established new business model for clinical stage biotechnology company, modelling risk-adjusted NPV for seven preclinical to clinical stage assets across therapeutic areas (e.g., Autoimmune / Immunology, Oncology, Cardio-metabolic, and Neurology) to assess current portfolio and develop future strategy, including franchise development, spinouts, and divestitures.Developed a global commercial and operational strategy for a U.S. biotech client for an Infectious Disease treatment (i.e., COVID-19), specifically focused on ex-U.S. market entry strategies, international pricing and reimbursement, and competitive pipeline analysisModeled market opportunity assessment in high beta, advanced modality therapy ingredient (e.g., pDNA) and conducted M&A screen for strategic buyer entrance into upstream therapeutic ingredient spaceModeled industry outlook for vendor due diligences (VDDs) in the following industries: pharmaceutical manufacturing equipment (e.g., fill-finish, lyophilization) and consumer health formulation contract development and manufacturing organization (CDMO) servicesCo-author on "COVID-19 Funding Snapshot for Pharma Developers/Manufacturers"

Boston, Ma, Us

Sample projects:Contributed to ~$75B biopharmaceutical post-merger integration across multiple teams:o Optimized ~300 external alliances through financial and therapeutic analysis, identifying ~$1B in potential synergies and developing implementation plano Developed product strategy for 25 peri-and-post-LoE assets, contributing ~$2B in potential EBIT increase over next 5 years while minimizing operational and medical risko Developed and managed resourcing plan and internal revenue forecast as Chief of Staff for ~70 person engagement, exceeding recovery rate goals by 5%Led team in a M&A screen for a top 10 biopharma to identify opportunities to diversify therapeutic area footprint, leading to diligence efforts on ~3 companies and ~$13B acquisitionDeveloped M&A strategy for $10B market cap oncology diagnostics company, culminating in a transformational merger and 50% gain in market capCommercial Due Diligence in the following sectors: consumer services, restaurant groups, paper and forest products, contract development and manufacturing for cell therapy, and industrials

Fort Worth, Texas, Us

• Formulated new social services by analyzing trends and managing seven projects, totaling $7M and reporting to C-suite executives, increasing new customers by 30%• Developed operating procedures, process workflows, and marketing strategy for a financial service program, resulting in a 70% customer conversion of the target population• Built a demand forecasting model for a call center by analyzing historical data, leading to an increase in staffing efficiency and customer satisfaction by 20% and ~5% respectively

Fort Worth, Tx, Us

• Executed personal strategy to develop program awareness by scheduling and managing over 30 daily client meetings to explain services leading to a 95% customer conversion• Awarded national performance rating of top 5% within over 600 person organization

Raleigh, North Carolina, Us

• Developed and deployed employee retention and performance improvement project by interviewing and surveying over 600 employees, which led to an increase in retention and performance by 15% and 10%, respectively • Formulated and delivered communications to build project awareness among over 600 impacted employees across 25 locations while maintaining optimal productivity levels

Washington, Dc, Us

• Analyzed program financial data and impact numbers for five public health program in three countries recommending results-based funding allocations to senior officials• Drafted articles highlighting U.S. positions on global issues by reporting the findings of expert panels and Congressional hearings which was then distributed to ~ 44,000 employees worldwide• Created a presentation on the possible U.S. Presidential election outcomes and the effects to U.N. funding which was used to inform then Secretary-General Ban Ki-Moon

Fort Worth, Tx, Us

• Managed all student records for Add-Ran College of Liberal Arts ensuring accuracy and compliance with federal regulations• Scheduled ~7,000 student appointments for college faculty and staff

Master'S Of Science, Biotechnology, Cell & Gene Therapy

Tuck Business Bridge Summer Program

Bachelor Of Science (B.S.), Political Science

Bachelor Of Arts (B.A.), Spanish Language And Literature